Natural History and Treatment Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Retrospective Longitudinal Cohort Study.
The first large study of rare congenital thrombotic thrombocytopenia documents disease burden and sets real-world benchmarks for testing new experimental therapies.
This first large multinational natural history study of congenital TTP (n=78, 9 sites, 8.1-year follow-up) quantifies substantial disease burden: most patients experience acute TTP events and organ complications, and while plasma prophylaxis reduces acute events, it fails to prevent ongoing manifestations or cumulative damage. Data establish validated real-world comparator benchmarks for emerging recombinant ADAMTS13 therapy trials.
What the study was
- Study design
- Retrospective multinational longitudinal cohort; 9 European and US sites; medical record abstraction; mean follow-up 8.1 years (2009-2020).
- Population
- 78 patients with congenital TTP (severe hereditary ADAMTS13 deficiency <10% activity); 61% female; 9 multinational sites.
- Sample size
- 78
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Health Economics and Outcomes Research
Why it surfaced
First large multinational natural history dataset for congenital TTP (ultra-rare, life-threatening); data support recombinant ADAMTS13 development and provide real-world comparator benchmarks. 78 patients is large for this ultra-rare disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.